NodThera, a Cambridge biotech company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, has advanced its lead development candidate, NT-0167, into pre-IND testing as it prepares to advance to the clinic.
The company has also strengthened its board with the addition of two industry leaders with deep experience developing novel treatments targeting compelling new areas of biology.
Don Nicholson, former CEO of Nimbus Therapeutics becomes chair and Kevin Lee, chief executive of Bicycle Therapeutics, has joined as an independent director.
NodThera president and CEO, Adam Keeney, said: “The field of NLRP3 inflammasome inhibitors is expanding rapidly with new insights highlighting the role of innate immunity in driving the chronic inflammation that is at the root of a wide range of serious diseases.
“The progression of our first development candidate represents an important milestone as we advance rapidly toward the clinic. We are thrilled to welcome Don and Kevin to the board and believe their strategic insights and deep experience in pioneering novel treatments across multiple disease areas will help us to build a truly transformational therapeutics company.”
NodThera is enhancing current understanding of innate immunity and the NLRP3 inflammasome’s role in chronic inflammation to develop a leading platform of small molecule therapeutics.
The company has made significant progress over the past two years in shaping the second-generation chemistry platform that builds on the innovation of NT-0167.
This article first appeared in Business Weekly, May 2nd 2019.